Neoadjuvant Dual Checkpo intInhibitors vs Anti-PD1 Therapy in High-Risk Resectable Melanoma: A Pooled Analysis(vol 10, pg 612, 2024)

被引：0
|
作者：
Mangla, A.
Lee, C.
Mirsky, M. M.
机构：
来源：
JAMA ONCOLOGY | 2024年 / 10卷 / 08期
关键词：
D O I：
10.1001/jamaoncol.2024.3182
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1138 / 1138
页数：1
相关论文
共 23 条
  • [21] Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score (vol 83, pg 432, 2024)
    Galsky, Matthew D.
    Bajorin, Dean F.
    Witjes, Johannes Alfred
    Gschwend, Juergen E.
    Tomita, Yoshihiko
    Nasroulah, Federico
    Li, Jun
    Collette, Sandra
    Valderrama, Begona P.
    Grimm, Marc-Oliver
    Appleman, Leonard
    Gravis, Gwenaelle
    Necchi, Andrea
    Ye, Dingwei
    Stenner, Frank
    Wind-Rotolo, Megan
    Zhang, Joshua
    uensal-Kacmaz, Keziban
    EUROPEAN UROLOGY, 2024, 85 (03) : e96 - e97
  • [22] Granulomatous and sarcoid-like immune adverse events following CTLA4 and PD1 blockade adjuvant therapy of high-risk melanoma: A combined analysis of ECOG-ACRIN E1609 and SWOG S1404 phase III trials
    Noor, A.
    Yassine, I.
    Lee, S. J.
    Othus, M.
    Moon, J.
    Kirkwood, J. M.
    Sondak, V.
    Ribas, A.
    Grossmann, K. F.
    Tarhini, A. A.
    ANNALS OF ONCOLOGY, 2021, 32 : S887 - S888
  • [23] IMvigor011: A global, double-blind, randomised phase III study of atezolizumab (atezo; anti-PD-L1) vs placebo (pbo) as adjuvant therapy in patients (pts) with high-risk muscle-invasive bladder cancer (MIBC) who are circulating tumour (ct)DNA plus post cystectomy
    Powles, T. B.
    Gschwend, J. E.
    Bracarda, S.
    Castellano, D.
    Gross-Goupil, M.
    Jensen, J. Bjerggaard
    Kann, A.
    Nishiyama, H.
    Makaroff, L.
    Lassidi, H.
    Mariathasan, S.
    Zhang, J.
    Degaonkar, V.
    Bellmunt, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S721 - S721
123